natgillin/translations-raw huggingface dataset:
The intravenous infusion is prepared by diluting Tractocile 37.5 mg/5 ml, concentrate for solution for infusion in sodium chloride 9 mg/ml (0.9%) solution for injection, Ringer's lactate solution or 5% w/v glucose solution. 
Raztopino zdravila za intravensko infuzijo se pripravi tako, da se zdravilo Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje razredči v 9 mg/ml (0,9 %) raztopini natrijevega klorida za injiciranje, raztopini Ringerjevega laktata ali 5 % (w/v) raztopini glukoze.
Replace it by 10 ml Tractocile 37.5 mg/5 ml concentrate for solution for infusion from two 5 ml vials to obtain a concentration of 75 mg atosiban in 100 ml. 
Nadomestite jo z 10 ml zdravila Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje, ki jih dobite iz dveh 5 ml vial, tako da bo končna koncentracija 75 mg atosibana v 100 ml.
One vial of concentrate for solution for infusion contains 5 ml solution, corresponding to 37.5 mg atosiban. 
Ena viala s koncentratom za raztopino za infundiranje vsebuje 5 ml raztopine, kar ustreza 37,5 mg atosibana.
Very common (affects more than 1 in 10 people) - feeling sick (nausea) 
Zelo pogosti (neželeni učinki, ki se lahko pojavijo pri več kot 1 od 10 bolnic) - Siljenje na bruhanje (navzea).
Tractocile is given intravenously in three successive stages: - The initial intravenous injection of 6.75 mg in 0.9 ml is slowly injected into a vein over one minute. 
Zdravilo Tractocile aplicirajte intravensko v treh zaporednih korakih: - Začetna intravenska injekcija 6,75 mg v 0,9 ml. Injicirajte počasi (tj. eno minuto) v veno.
Tractocile will be given into a vein (intravenously) in three stages: - The first injection of 6.75 mg in 0.9 ml will be slowly injected into your vein over one minute. 
Zdravilo Tractocile boste prejeli v veno (intravensko) v treh korakih: - Najprej boste v veno prejeli počasno injekcijo s 6,75 mg v 0,9 ml. Injiciranje zdravila bo trajalo eno minuto.
12 hours. 
ure.
- if your unborn baby has died. 
- Če je plod odmrl.
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC (IZDELOVALCI) ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja srbenje, kožni izpuščaj
Each ml of solution contains 7.5 mg atosiban. 
En ml raztopine vsebuje 7,5 mg atosibana.
Atosiban passes the placenta. 
Atosiban prehaja skozi placento.
6.1 List of excipients 
6.1 Seznam pomožnih snovi manitol
This will mean your unborn baby needs to be delivered straight away. 
V tem primeru je treba porod opraviti takoj.
- A continuous infusion at a rate of 8 ml/hour is given for up to 45 hours, or until the contractions of the uterus have subsided. 
Infundiranje traja do 45 ur ali dokler kontrakcije uterusa ne popustijo.
The Tractocile 6.75 mg/0.9 ml, solution for injection should be used immediately. 
Zdravilo Tractocile 6,75 mg/0,9 ml raztopina za injiciranje morate uporabiti takoj.
What Tractocile looks like and contents of the pack Tractocile 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. 
Zdravilo Tractocile 6,75 mg/0,9 ml raztopina za injiciranje je bistra, brezbarvna raztopina brez delcev.
Tractocile works by making the contractions in your womb (uterus) less strong. 
Zdravilo Tractocile ublaži in zmanjša pogostnost materničnih kontrakcij (popadkov).
For intravenous infusion, following the bolus dose, Tractocile 37.5 mg/5 ml, concentrate for solution for infusion should be diluted in one of the following solutions: sodium chloride 9 mg/ml (0.9%) solution for injection Ringer's lactate solution 
Za pripravo intravenske infuzije, ki sledi bolusnemu odmerku, je treba zdravilo Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje razredčiti z eno od naslednjih raztopin: - 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida, - raztopino Ringerjevega laktata, - 5-odstotno (w/v) raztopino glukoze.
Preparation of the intravenous infusion solution: 
Priprava raztopine za intravensko infundiranje:
There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys. 
Pri bolnicah z okvaro delovanja jeter ali ledvic ni izkušenj z uporabo atosibana.
Clear, colourless solution without particles. 
raztopina za injiciranje (injekcija) Bistra, brezbarvna raztopina brez delcev.
One vial of 5 ml contains 37.5 mg of atosiban (as acetate). 
Ena viala s 5 ml vsebuje 37,5 mg atosibana (v obliki acetata).
This is done by removing 10 ml of solution from a 100 ml infusion bag and replacing it with 10 ml Tractocile 37.5 mg/5 ml concentrate for solution for infusion from two 5 ml vials to obtain a concentration of 75 mg atosiban in 100 ml. 
Iz 100 ml infuzijske vrečke odstranite 10 ml raztopine in jo nadomestite z 10 ml zdravila Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje iz dveh 5 ml vial.
If you get any side effects, talk to your doctor, midwife or pharmacist. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom, babico ali farmacevtom.
Once the vial has been opened, the dilution must be performed immediately. 
Raztopino je treba uporabiti takoj po odprtju viale.
One vial of 0.9 ml contains 6.75 mg of atosiban (as acetate). 
Ena viala z 0,9 ml vsebuje 6,75 mg atosibana (v obliki acetata).
Preparation of the intravenous infusion 
Priprava raztopine za intravensko infundiranje
Österreich Ferring Arzneimittel Ges.m.b.H 
Deutschland Ferring Arzneimittel GmbH
Reproductive system and breast disorder 
Motnje reprodukcije in dojk maternična krvavitev, atonija maternice
- if you have something called “eclampsia” which is similar to “severe pre-eclampsia” but you would also have fits (convulsions). 
Bolezenski znaki eklampsije so podobni kot pri hudi preeklampsiji,
Nausea Vomiting 
Bolezni prebavil navzea bruhanje
Concentrate for solution for infusion (sterile concentrate). 
koncentrat za raztopino za infundiranje (sterilni koncentrat) Bistra, brezbarvna raztopina brez delcev.
Do not use Tractocile if any of the above apply to you. 
Če se karkoli od navedenega nanaša na vas, zdravila Tractocile ne smete prejeti.
Uterine haemorrhage, uterine atony 
Hitrost infundiranja Odmerek atosibana
Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate). 
Ena viala z 0,9 ml raztopine vsebuje 6,75 mg atosibana (v obliki acetata).
Each vial of 5 ml solution contains 37.5 mg atosiban (as acetate). 
Ena viala s 5 ml raztopine vsebuje 37,5 mg atosibana (v obliki acetata).
Uncommon (affects less than 1 in 100 people) - high temperature (fever) - difficulty sleeping (insomnia) - itching - rash 
Občasni (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 100 bolnic) - Zvišana telesna temperatura (vročina).
Tractocile 37.5 mg/5 ml sterile concentrate atosiban 
Tractocile 37,5 mg/5 ml sterilni koncentrat atosiban i.v.
The vials should be inspected visually for particulate matter and discoloration prior to administration. 
Viale je treba pred uporabo pregledati, da ne vsebujejo delcev oziroma, da vsebina ni spremenila barve.
Tractocile 6.75 mg/0.9 ml injection atosiban 
Tractocile 6,75 mg/0,9 ml injekcija atosiban i.v.
Tractocile 37.5 mg/5 ml concentrate for solution for infusion Atosiban 
Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje atosiban
Atosiban dose 
Odmerjanje
Further treatment with Tractocile can be used if your contractions start again. 
Če se kontrakcije maternice zopet začnejo, se lahko zdravljenje z zdravilom Tractocile ponovi.
Tractocile 6.75 mg/0.9 ml solution for injection 
Tractocile 6,75 mg/0,9 ml raztopina za injiciranje
Tractocile 37.5 mg/5 ml concentrate for solution for infusion is a clear, colourless solution without particles. 
Izgled zdravila Tractocile in vsebina pakiranja Zdravilo Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje je bistra, brezbarvna raztopina brez delcev.
Tractocile 37.5 mg/5 ml concentrate for solution for infusion 
Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje
Further treatment cycles of Tractocile can be used should contractions recur. 
Če se kontrakcije uterusa ponovijo, se lahko cikel zdravljenja z zdravilom Tractocile ponovi.
Provides 0.75 mg/ml when diluted as recommended. 
Po priporočenem redčenju vsebuje 0,75 mg/ml.
- Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 45 hours, or until your contractions have stopped. 
- Nato boste prejeli še drugo kontinuirano (kapalno) infuzijo v odmerku 6 mg na uro.
Immune system disorders 
Bolezni imunskega sistema alergijska reakcija
- Each vial of Tractocile 37.5 mg/5 ml concentrate for solution for infusion contains atosiban acetate equivalent to 37.5 mg of atosiban in 5 ml. 
- Ena viala zdravila Tractocile 37,5 mg/5 ml koncentrat za raztopino za infundiranje vsebuje atosibanijev acetat, ki ustreza 37,5 mg atosibana v 5 ml. - Pomožne snovi so manitol, klorovodikova kislina in voda za injekcije.
Tractocile contains atosiban. 
Zdravilna učinkovina zdravila Tractocile je atosiban.
MedDRA System Organ Class (SOC) 
Razvrstitev organskih sistemov po MedDRA
Gestational age below 24 or over 33 completed weeks Premature rupture of the membranes >30 weeks of gestation Abnormal foetal heart rate 
- gestacijska starost pod 24 ali nad 33 dopolnjenih tednov, - prezgoden razpok plodnega mehurja > 30 tednov gestacije, - nenormalna srčna frekvenca ploda, - predporodna maternična krvavitev, ki zahteva takojšen porod, - eklampsija ali huda preeklampsija, ki zahtevata porod, - intrauterino odmrtje ploda, - sum na intrauterino okužbo, - placenta praevia, - abruptio placentae, - katerokoli drugo stanje pri materi ali plodu, zaradi katerega je nadaljevanje nosečnosti tvegano, - preobčutljivost na zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
The following side effects may happen with this medicine: Very common (affects more than 1 in 10 people) - feeling sick (nausea) 
Pogosti (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 10 bolnic) - Glavobol.
Nervous system disorders 
Bolezni živčevja glavobol, omotica
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed. 
Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je potreben boljši nadzor glukoze (sladkorja) v krvi.
The recommended starting dose of Pioglitazone Krka is 15 or 30 mg once a day. 
Priporočeni začetni odmerek zdravila Pioglitazone Krka je 15 ali 30 mg enkrat dnevno.
The full EPAR for Pioglitazone Krka can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pioglitazone Krka je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Krka on 21 March 2012. 
Evropska Komisija je dovoljenje za promet z zdravilom Pioglitazone Krka, veljavno po vsej Evropski uniji, odobrila dne 21. marca 2012.
At subsequent reviews prescribers should confirm that benefits to patients are maintained. 
Pri nadaljnjih pregledih morajo zdravniki, ki zdravilo predpisujejo, preveriti, ali se koristi za bolnike ohranjajo.
Treatment with Pioglitazone Krka should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. 
Zdravljenje z zdravilom Pioglitazone Krka je treba po treh do šestih mesecih proučiti in prekiniti pri bolnikih, pri katerih ni zadostne koristi.
For more information about treatment with Pioglitazone Krka, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pioglitazone Krka preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This means that Pioglitazone Krka is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
The active substance in Pioglitazone Krka, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Zdravilna učinkovina zdravila Pioglitazone Krka, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
What are the benefits and risks of Pioglitazone Krka? 
Kakšne so koristi in tveganja, povezani z zdravilom Pioglitazone Krka?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pioglitazone Krka. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Pioglitazone Krka, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Pioglitazone Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Pioglitazone Krka generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Pioglitazone Krka is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. 
Zdravilo Pioglitazone Krka se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
This is a summary of the European public assessment report (EPAR) for Pioglitazone Krka. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pioglitazone Krka.
Because Pioglitazone Krka is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos. 
Ker je zdravilo Pioglitazone Krka generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
Pioglitazone Krka should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease). 
Zdravilo Pioglitazone Krka se ne sme uporabljati pri bolnikih na dializi (tehniki čiščenja krvi, uporabljeni pri bolnikih z obolenjem ledvic).
Pioglitazone Krka is a ‘generic medicine'. 
Zdravilo Pioglitazone Krka je generično zdravilo.
The CHMP concluded that, in accordance with EU requirements, Pioglitazone Krka has been shown to have comparable quality and to be bioequivalent to Actos. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone Krka primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
Pioglitazone Krka is a medicine that contains the active substance pioglitazone. 
Pioglitazone Krka je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
Pioglitazone Krka can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin. 
Zdravilo Pioglitazone Krka se lahko uporablja tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana z insulinom samim in za katere metformin ni primeren.
Pioglitazone Krka can also be used with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy'). 
Zdravilo Pioglitazone Krka se lahko uporablja tudi s sulfonilsečnino (drugo zdravilo proti sladkorni bolezni), če metformin ni primeren (dvojno zdravljenje).
The Committee recommended that Pioglitazone Krka be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Pioglitazone Krka odobri dovoljenje za promet.
Other information about Pioglitazone Krka 
Druge informacije o zdravilu Pioglitazone Krka
Pioglitazone Krka is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable. 
Zdravilo Pioglitazone Krka se uporablja samostojno pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primerno.
Why has Pioglitazone Krka been approved? 
Zakaj je bilo zdravilo Pioglitazone Krka odobreno?
How has Pioglitazone Krka been studied? 
Kako je bilo zdravilo Pioglitazone Krka raziskano?
What is Pioglitazone Krka used for? 
Za kaj se zdravilo Pioglitazone Krka uporablja?
How is Pioglitazone Krka used? 
Kako se zdravilo Pioglitazone Krka uporablja?
How does Pioglitazone Krka work? 
Kako zdravilo Pioglitazone Krka deluje?
What is Pioglitazone Krka? 
Kaj je zdravilo Pioglitazone Krka?
In the MRP United Kingdom is the Reference Member State (RMS) and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and Sweden are Concerned Member States (CMS). 
V postopku medsebojnega priznavanja je bilo Združeno kraljestvo referenčna država članica, medtem ko so bile Avstrija, Belgija, Finska, Francija, Nemčija, Italija, Irska, Luksemburg, Portugalska, Španija in Švedska zadevne države članice.
VIANI EVOHALER and associated names (See Annex I) 
VIANI EVOHALER in z njim povezana imena (glejte Dodatek I)
In several EU Member States Viani Evohaler and associated names are approved through the Mutual Recognition Procedure (MRP). 
V številnih državah članicah EU je bilo zdravilo Viani Evohaler in z njim povezana imena odobreno s postopkom medsebojnega priznavanja (MRP).
Viani Evohaler and associated names (see Annex I) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist salmeterol and the inhaled corticosteroid fluticasone propionate and is indicated for the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. 
Zdravilo Viani Evohaler in z njim povezana imena (glejte Dodatek I), ki vsebuje salmeterol in flutikazon propionat, kombinacijo fiksnih odmerkov dolgo delujočega β-agonista (LABA) salmeterola in inhalacijskega kortikosteroida (ICS) flutikazon propionata (FP), je indicirano za običajno zdravljenje astme, kadar je uporaba kombiniranega zdravila (dolgo delujočega beta-2-agonista in inhalacijskega kortikosteroida) ustrezna: pri bolnikih, pri katerih z inhalacijskimi kortikosteroidi in »po potrebi« z inhalacijskim kratko delujočim beta-2-agonistom ni mogoče doseči zadostnega nadzora bolezni, ali pri bolnikih, pri katerih je bilo mogoče že z inhalacijskimi kortikosteroidi in dolgo delujočim beta-2-agonistom vzpostaviti zadosten nadzor bolezni.
It is available as a solution for injection which should be given by a healthcare professional about 30 minutes before the start of chemotherapy. 
Na voljo je v obliki raztopine za injiciranje, ki jo mora injicirati zdravstveni delavec približno 30 minut pred začetkom kemoterapije.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Palonosetron Hospira has been shown to be comparable to Aloxi. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Palonosetron Hospira primerljivo z zdravilom Aloxi.
The full EPAR for Palonosetron Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Palonosetron Hospira je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In adults, the recommended dose is 250 micrograms, injected into a vein over 30 seconds. 
Priporočeni odmerek pri odraslih je 250 mikrogramov, ki se 30 sekund injicira v veno.
This is a summary of the European public assessment report (EPAR) for Palonosetron Hospira. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Palonosetron Hospira.
This means that it stops a chemical in the body called 5-hydroxytryptamine (5HT, also known as serotonin) from attaching to 5HT3 receptors in the gut. 
To pomeni, da kemični snovi v telesu, imenovani 5-hidroksitriptamin (5HT, znani tudi kot serotonin), prepreči vezavo na receptorje 5HT3 v črevesju.
It is used in adults and children 1 month of age or older for chemotherapy with medicines that are either a strong trigger of nausea and vomiting (such as cisplatin) or a moderate trigger (such as cyclophosphamide, doxorubicin or carboplatin). 
Uporablja se pri odraslih in otrocih, starejših od enega meseca, pri kemoterapiji z zdravili, ki povzročajo bodisi močno slabost in bruhanje (kot je cisplatin) bodisi zmerno (kot so ciklofosfamid, doksorubicin ali karboplatin).
The Committee recommended that Palonosetron Hospira be approved for use in the EU. 
Priporočil je, da se zdravilo Palonosetron Hospira odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Palonosetron Hospira? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Palonosetron Hospira?
Because Palonosetron Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Palonosetron Hospira generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
A risk management plan has been developed to ensure that Palonosetron Hospira is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Palonosetron Hospira je bil pripravljen načrt obvladovanja tveganj.
The company provided data from the published literature on palonosetron. 
Družba je predstavila podatke o palonosetronu iz objavljene literature.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Palonosetron Hospira, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
This means that Palonosetron Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aloxi. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Aloxi.
What are the benefits and risks of Palonosetron Hospira? 
Kakšne so koristi in tveganja, povezani z zdravilom Palonosetron Hospira?
It may be given with a corticosteroid (another type of medicine that can be used to prevent nausea and vomiting) to increase the effect. 
Za povečanje učinkovitosti se mu lahko doda kortikosteroid (drugo vrsta zdravila, ki se lahko uporablja za preprečevanje slabosti in bruhanja).
For more information about treatment with Palonosetron Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Palonosetron Hospira preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using Palonosetron Hospira, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Palonosetron Hospira naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
By blocking these receptors, Palonosetron Hospira prevents the nausea and vomiting that often happen after chemotherapy. 
Zdravilo Palonosetron Hospira z zaviranjem teh receptorjev prepreči slabost in bruhanje, ki se pogosto pojavita po kemoterapiji.
Other information about Palonosetron Hospira 
Druge informacije o zdravilu Palonosetron Hospira